600mg Package Label (058 Sun)
Gabapentin
Product Images NDC 21695-059
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 21695-059). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
800mg Package Label (059 Sun)
Gabapentin-fig01 (Gabapentin Fig01)
The text describes a graph (Figure 1) showing weekly mean pain scores (Observed Cases in ITT Population) for Study 1. The graph includes a 4-week dose titration period, a 4-week fixed dose period, and two treatment groups: Placebo and Gabapentin, 3600 mg/day. The values of the baseline, weeks 1 through 8, and the significance level (p<0.01) are presented.*
Gabapentin-fig02 (Gabapentin Fig02)
The text represents data from a study regarding mean pain scores. The study consists of a 3-week dose titration period and a 4-week fixed dose period. Gabapentin is used at two different doses and a placebo is also used. There is a graph showing weekly mean pain scores from baseline through week 7. The data suggests that gabapentin at both doses is statistically significant in reducing pain compared to the placebo.*
Gabapentin-fig03 (Gabapentin Fig03)
The text describes a figure named "Figure 3" that shows the percentage of patients who responded positively to treatment (with a reduction of at least 50% in pain score) in two controlled studies for PHN (postherpetic neuralgia), using two different doses of GBP (gabapentin) and a placebo (PBO). It also includes a note about statistical significance based on p-values.*
Gabapentin-fig04 (Gabapentin Fig04)
The text describes a figure showing the Responder Rate of Gabapentin at various daily doses in patients over 12 years of age with Partial Seizures. There are different studies shown in the figure, and the Responder Rate is expressed as a difference from Placebo.*
Gabapentin-structure (Gabapentin Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
